Literature DB >> 12160579

Radical prostatectomy by the retropubic, perineal and laparoscopic approach: 12 years of experience in one center.

Laurent Salomon1, Olivier Levrel, Alexandre de la Taille, Aristotelis G Anastasiadis, Fabien Saint, Safawat Zaki, Dimitrios Vordos, Antony Cicco, L Eric Olsson, Andras Hoznek, Dominique Chopin, Clement-Claude Abbou.   

Abstract

OBJECTIVES: We retrospectively evaluated the oncological outcome of radical prostatectomy performed by the retropubic, perineal and laparoscopic approaches.
METHODS: From 1988 to 2000, 401 patients underwent radical prostatectomy for localized prostate cancer by the retropubic, perineal or laparoscopic approach. Age, clinical stage, preoperative PSA and Gleason score of positive biopsies were noted. Operating time, complication rate, transfusion rate, length of hospital stay, catheterization time and pathological results were reviewed. Kaplan-Meier analysis was used to evaluate the likelihood of biochemical recurrence (PSA > or =0.2 ng/ml).
RESULTS: There were no significant differences between the three groups regarding preoperative characteristics, except for PSA (21.4 ng/ml, 13.2 ng/ml, and 11.6 ng/ml for the retropubic, perineal, and laparoscopic approach, p<0.05) and the frequency of stage T1c tumors (31.7%, 47.1% and 63.5%, respectively, p<0.05). The operating time was significantly longer in the laparoscopic approach (285 min) compared to the retropubic and perineal techniques (197 min and 178 min, respectively). The retropubic approach was associated with a higher transfusion rate (26.2% versus 15.9% and 2.9% with the perineal and laparoscopic approaches), longer bladder catheterization time (15.9 days versus 11.7 days and 6.8 days, respectively), and longer hospital stay (15.2 days versus 8.5 days and 7.4 days, respectively) (p<0.05 for each). With the retropubic, perineal and laparoscopic approaches, medical complication rates were 8.3%, 4.2% and 5.1%, and surgical complication rates were 16.5%, 12.7% and 13.1%, respectively. The rates of pathological stage pT2 tumors were 62.1%, 72.2% and 75.9%, in the retropubic, perineal and laparoscopic groups, respectively. Positive surgical margins in pT2 tumors were noted in 19%, 14% and 22%, respectively. The actuarial 3-year recurrence-free survival rates were not significantly different between the three techniques (75%, 85.2% and 84.1%, respectively; 91.7%, 95.8% and 90.4% among patients with organ-confined tumors).
CONCLUSION: Despite changes in patient selection criteria over time, and the relatively short follow-up, this study showed no significant difference in oncologic outcome between the retropubic, perineal and laparoscopic approaches to radical prostatectomy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12160579     DOI: 10.1016/s0302-2838(02)00263-4

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  28 in total

Review 1.  Laparoscopic radical prostatectomy: review and assessment of an emerging technique.

Authors:  J B Basillote; T E Ahlering; D W Skarecky; D I Lee; R V Clayman
Journal:  Surg Endosc       Date:  2004-10-26       Impact factor: 4.584

Review 2.  [Laparoscopic pelvic surgery: Where do we stand in the year 2006?].

Authors:  J Rassweiler; D Teber; J de la Rosette; P Laguna; V Pansodoro; T Frede
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

Review 3.  Oncological and functional results of open, robot-assisted and laparoscopic radical prostatectomy: does surgical approach and surgical experience matter?

Authors:  T R Herrmann; R Rabenalt; J U Stolzenburg; E N Liatsikos; F Imkamp; H Tezval; A J Gross; U Jonas; M Burchardt
Journal:  World J Urol       Date:  2007-03-13       Impact factor: 4.226

Review 4.  Robot-assisted versus pure laparoscopic radical prostatectomy.

Authors:  Francois Rozet; Justin Harmon; Xavier Cathelineau; Eric Barret; Guy Vallancien
Journal:  World J Urol       Date:  2006-03-17       Impact factor: 4.226

5.  Comparison of mid-term carcinologic control obtained after open, laparoscopic, and robot-assisted radical prostatectomy for localized prostate cancer.

Authors:  Sarah J Drouin; Christophe Vaessen; Vincent Hupertan; Eva Comperat; Vincent Misraï; Alain Haertig; Marc-Olivier Bitker; Emmanuel Chartier-Kastler; François Richard; Morgan Rouprêt
Journal:  World J Urol       Date:  2009-05-07       Impact factor: 4.226

6.  A multi-institutional comparison of radical retropubic prostatectomy, radical perineal prostatectomy, and robot-assisted laparoscopic prostatectomy for treatment of localized prostate cancer.

Authors:  Eric E Coronato; Justin D Harmon; Phillip C Ginsberg; Richard C Harkaway; Kulwant Singh; Leonard Braitman; Bruce B Sloane; Jamison S Jaffe
Journal:  J Robot Surg       Date:  2009-10-01

7.  Radical prostatectomy--too soon to abandon the perineal approach?

Authors:  Vinod H Nargund; Faruquz Zaman
Journal:  Nat Rev Urol       Date:  2011-04       Impact factor: 14.432

8.  Long-term oncological and functional results of extraperitoneal laparoscopic radical prostatectomy: one surgical team's experience on 1,600 consecutive cases.

Authors:  Paolo Verze; Salvatore Scuzzarella; Giorgio R Martina; Pierluigi Giummelli; Federico Cantoni; Vincenzo Mirone
Journal:  World J Urol       Date:  2013-03-17       Impact factor: 4.226

9.  Body mass index as a classifier to predict biochemical recurrence after radical prostatectomy in patients with lower prostate-specific antigen levels.

Authors:  Keisuke Goto; Hirotaka Nagamatsu; Jun Teishima; Yuki Kohada; Shinsuke Fujii; Yoshimasa Kurimura; Koji Mita; Masanobu Shigeta; Satoshi Maruyama; Yoji Inoue; Mitsuru Nakahara; Akio Matsubara
Journal:  Mol Clin Oncol       Date:  2017-04-10

10.  Assessment of low prostate weight as a determinant of a higher positive margin rate after laparoscopic radical prostatectomy: a prospective pathologic study of 1,500 cases.

Authors:  Peiguo G Chu; Sean K Lau; Lawrence M Weiss; Mark Kawachi; Jeffrey Yoshida; Christopher Ruel; Rebecca Nelson; Laura Crocitto; Timothy Wilson
Journal:  Surg Endosc       Date:  2008-09-24       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.